Oxaliplatin/CPT-11 for Extensive Stage Small Cell Lung Cancer
Part of paid clinical trials in Seattle, Washington.
- Sponsor
- Swedish Medical Center
- Study ID
- NCT00316433
- Phase
- PHASE2
- Status
- Terminated
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Irinotecan (CPT-11) — DRUG
- Oxaliplatin (Eloxatin) — DRUG
Study Details
The purpose of this study is to determine the safety and effectiveness of the combination of oxaliplatin and irinotecan (CPT-11) in patients with previously untreated, advanced small cell lung cancer.
Key Dates
- Start date
- Feb 28, 2005
- Status verified
- Apr 2007
- Completion
- Jan 31, 2007
Study Design
- Enrollment
- 24 participants
- Allocation
- NON_RANDOMIZED
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Swedish Medical Center Cancer Institute | Seattle | Washington | 98104 | - |
Find similar trials in Seattle, WA
By condition
By specialty
By research site
Related Studies
- The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)PHASE1/PHASE2 · Recruiting · PMV Pharmaceuticals, Inc · Irvine, California
- Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid TumorsPHASE1 · Recruiting · SystImmune Inc. · Beverly Hills, California
- Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain MetastasisPHASE1/PHASE2 · Recruiting · Neonc Technologies, Inc. · Beverly Hills, California
- A Study of Alisertib in Patients With Extensive Stage Small Cell Lung CancerPHASE2 · Recruiting · Puma Biotechnology, Inc. · Daphne, Alabama